# EDGAR Filing Document

**Accession Number:** 0001860871
**File Stem:** 0000000000-25-006572
**Filing Date:** 2025-6
**Character Count:** 2313
**Document Hash:** d8b377648f3072061d1ae3b366234dfc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006572.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0000000000-25-006572

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250624

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tevogen Bio Holdings Inc.
- **CENTRAL INDEX KEY:** 0001860871
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981597194
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288218

**BUSINESS ADDRESS:**
- **STREET 1:** 15 INDEPENDENCE BOULEVARD, SUITE #210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059
- **BUSINESS PHONE:** 646-807-8832

**MAIL ADDRESS:**
- **STREET 1:** 15 INDEPENDENCE BOULEVARD, SUITE #210
- **CITY:** WARREN
- **STATE:** NJ
- **ZIP:** 07059

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Semper Paratus Acquisition Corp
- **DATE OF NAME CHANGE:** 20210505
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-015914

## Text-Extract

```

                                                           June 24, 2025

Ryan Saadi
Chief Executive Officer
Tevogen Bio Holdings Inc.
15 Independence Boulevard, Suite #210
Warren, NJ 07059

       Re: Tevogen Bio Holdings Inc.
           Registration Statement on Form S-3
           Filed June 20, 2025
           File No. 333-288218
Dear Ryan Saadi:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   William Intner, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._